Stereotaxis reported its financial results for the second quarter ended June 30, 2025, on August 7, 2025, with total revenue reaching $8.8 million. This represents a 95% increase compared to $4.5 million in the prior year's second quarter and an 18% sequential increase from Q1 2025.
System revenue for the quarter was $3.0 million, a significant increase from $0.2 million in the prior year, reflecting partial revenue recognition on two capital systems, including the first commercial GenesisX system. Recurring revenue grew 35% year-over-year to $5.8 million, driven by Map-iT catheter revenue and the initial launch of the MAGiC ablation catheter.
The company reported an operating loss of $4.0 million and a net loss of $3.8 million. Gross margin for the quarter was 52%. Stereotaxis reiterated its expectation for double-digit revenue growth for the full year 2025, with recurring revenue projected to scale to $7 million in the fourth quarter. The company's proforma cash balance, incorporating the $12.5 million registered direct financing, would be $18.8 million, strengthening its balance sheet to accelerate adoption of its innovation strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.